Medicus Pharma Ltd (TSE:MDCX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Medicus Pharma Ltd. has entered into an agreement with Swanielle Inc. to expand its Phase 2 clinical study for Basal Cell Carcinoma into the Asia-Pacific region. The ongoing study in the U.S. has already enrolled over 25% of the expected patients, with plans for an interim data analysis in early 2025 to accelerate its development program. The company aims to transition this exploratory trial into a pivotal one, potentially fast-tracking the treatment’s clinical pathway.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
